10-Q quarterly report · filed Oct 29, 2026

Alnylam Pharmaceuticals (ALNY) Q3 2026 10-Q Quarterly Report

Short answer

Alnylam Pharmaceuticals (ALNY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.5B (up 16.7% year over year) with net income of $2.2B.

Q3 2026 key financials · XBRL

Revenue
$1.5B
+16.7% YoY · −40.7% QoQ
Net income
$2.2B
+763.2% YoY · +485.0% QoQ
Operating margin
23.7%
EPS (diluted)
$15.71
+726.8% YoY · +479.7% QoQ

Source: XBRL data from the Alnylam Pharmaceuticals (ALNY) Q3 2026 10-Q on SEC EDGAR. USD.

Alnylam Pharmaceuticals Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $1.458B, up from $1.249B YoY, a $209.1M increase
  • Operating margin 23.7% vs 29.5% YoY, net income $2.167B vs $292.7M
  • Best performer AMVUTTRA: $1.130B revenue vs $685.3M, up $445.1M
  • Worst performer ONPATTRO: $19.6M revenue vs $39.1M, down $19.5M
  • Nine-month operating cash flow $738.2M vs $306.4M, with $700.7M used in investing activities

Risk Factors

  • New regulatory risk: October 2025 subpoena on government price reporting for four products, with U.S. Attorney engagement continuing
  • New legal risk: Cipla’s September 2026 lawsuit challenging AMVUTTRA patents through an FDA generic application
  • Operational risk: AMVUTTRA generic competition could affect product sales following Cipla’s abbreviated new drug application
  • Financial risk: $362.8 million of 2027 convertible notes classified current, maturing September 15, 2027
  • Collaboration risk: Regeneron’s Initial Research Term expired in May 2026, ending exclusivity for new eye and CNS discovery programs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Alnylam Pharmaceuticals quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.